The rationale for utilizing BET inhibitors as a potential treatment option for HPV-positive tumors is supported by the analysis of The Cancer Genome Atlas (TCGA) data, which revealed elevated expression and activity of Brd2, Brd3, and Brd4 in HPV-positive HNSCC tumors compared to normal tissue. Here, BRD2 is linked to head and neck squamous cell carcinoma.